If you've spent any time on social media, listened to a longevity podcast, or visited a wellness clinic recently, you've probably heard about peptides. They are being promoted for everything from weight loss and muscle growth to injury recovery, better sleep, improved skin, increased energy, and even longevity.
- Some of the science is genuinely fascinating.
- Some of the claims are far ahead of the science.
- And some products being injected into people today have remarkably little human safety data behind them.
So, what exactly is a peptide, and how do you separate promising medicine from unintentionally becoming part of a very large experiment?
First: What Is a Peptide?
Peptides are short chains of amino acids - the same building blocks that make up proteins. Our bodies naturally produce thousands of them, which often function as biological messengers.
A peptide can bind to a receptor and essentially deliver an instruction:
Release a hormone. Reduce appetite. Stimulate a signaling pathway. Influence inflammation. Change cellular activity.
This ability to target specific biological pathways is exactly what makes peptides so interesting to pharmaceutical researchers. And peptide medicine is certainly not new.
Insulin is a peptide.
Many modern GLP-1–based medications are peptide therapeutics. Numerous other FDA-approved peptide drugs are used in endocrinology, oncology, and other specialties. So peptides themselves are not “alternative medicine.”
In fact, they represent one of the most exciting areas of modern drug development.
Then What's the Problem?
The word peptide has become an umbrella term that can give very different products an undeserved appearance of equivalence. In fact, saying “I want to try peptides” is like saying “I want to try pills”.
An FDA-approved peptide medication that has undergone controlled clinical trials, manufacturing standards and regulatory review is very different from an experimental peptide purchased online with a label stating:
“For research use only. Not for human consumption.”
In fact these are screenshots, straight from current popular online peptide suppliers:
Yet both may be discussed simply as “peptide therapy.” But that distinction matters.
FDA-approved drugs undergo multiple phases of clinical trials before being offered to patients, including extensive evaluation for identity, purity, manufacturing consistency, dosing, effectiveness, and safety.
Compounded medications occupy a different regulatory category and are not FDA-approved products, but can be identical to FDA-approved products in cases of nationwide shortages or to generic medications. Compounding pharmacies are essential for hospitals, clinics, and patients alike. However, caution should be exercised when choosing one, and a serious vetting process should be done by the provider writing the prescription.
And then there is another rapidly expanding category: peptides that remain investigational, some with zero to minimal human research, being marketed directly to consumers for wellness, longevity or performance. These
research-only peptides have a label on them that should not be ignored: "not for human or animal use".
In fact, I have been approached by multiple suppliers of these research-only peptides for Aesthera. When I inquired about the not for human use products, I was told, "Don't worry, we will take that label off before you sell it to patients. Unfortunately, that is exactly what many Medspas are doing right now, making quite the profit while patients are completely unaware of what is actually going on.
This is where enthusiasm needs to be tempered with caution.
The Wild West of “Research Peptides”
Many experimental peptides have intriguing laboratory or animal data. But an important principle of medicine is often forgotten:
Biological plausibility is not the same thing as proven clinical safety or benefit. A molecule may improve tendon healing in a rodent, alter inflammation in a laboratory model or activate a theoretically desirable cellular pathway.
That does not automatically tell us:
- Whether it works in humans
- What dose is appropriate
- What happens after years of exposure
- Whether it interacts with medications or disease
- Whether stimulating that pathway has unintended consequences elsewhere in the body.
And when a product comes from an unregulated online source, there is an additional question:
Do we even know what is in the vial?
Sterility, concentration, contamination, degradation, peptide aggregation and impurities all matter, particularly when a substance is being injected. With peptides, impurities are not merely a manufacturing inconvenience. They can potentially provoke immune responses, and some peptides are structurally complex enough that characterization and consistency are challenging.
What we know vs what is marketed:
It’s possible some of these peptides will do nothing. Some peptides break down very quickly in the body, so using them could be the equivalent of injecting yourself with an expensive cocktail of amino acids. But they could also have unintended negative effects on the users’ health.
In animal studies, researchers have seen that some peptides, when used over a period of weeks or months, lead to cancer, organ damage, or neurotoxicity. Some can even aggregate into plaques in the body, mimicking the amyloid-beta plaques that are the hallmark of Alzheimer’s disease.
The bottom line is, they could cause all sorts of effects that are specific to that particular peptide that wouldn’t be immediately obvious. If a person takes them and they feel good, that doesn’t mean that they are good for long term. The recent proposal to the FDA to allow several peptides to be produced at compounding pharmacies does not change the clinical data.
The Peptides You're Hearing About -
see reference summary table at end of article
BPC-157 - “The Healing Peptide”
Perhaps no peptide better illustrates the gap between enthusiasm and evidence.
BPC-157 is widely promoted for tendon and ligament injuries, gastrointestinal healing, inflammation, and accelerated recovery. Preclinical research has produced intriguing findings.
The problem is the human evidence.
Despite enormous online popularity, high-quality human clinical data remain extremely limited. Questions regarding appropriate dosing, long-term safety, reproductive effects, cancer risk and other potential consequences remain unanswered.
FDA has specifically raised concerns about compounded BPC-157, including potential immunogenicity, peptide impurities, and insufficient safety information to determine whether it may cause harm in humans.
Verdict: Fascinating molecule. Very interesting preclinical science. Nowhere near the level of human evidence its online popularity would suggest.
TB-500 / Thymosin Beta-4 Fragment - Tissue Repair & Recovery
TB-500 is marketed for muscle, tendon and wound healing and is especially popular in performance and recovery communities.
Again, there are biologically interesting mechanisms involving cellular migration, blood-vessel formation, and tissue repair.
But those same mechanisms illustrate an important concept:
A biological pathway is rarely exclusively “good.”
Stimulating cell migration or angiogenesis may theoretically assist healing-but those processes are also involved in other diseases, including cancer biology.
For the commonly marketed thymosin beta-4 fragment known as TB-500, FDA has noted the lack of human exposure data and insufficient information to determine its safety.
Verdict: Interesting biology; inadequate evidence to justify the confidence with which it is often marketed.
CJC-1295 + Ipamorelin - Growth Hormone Signaling
These peptides are commonly marketed together to increase growth hormone secretion, with claims involving improved body composition, sleep, recovery, muscle mass, and “anti-aging.” The physiology is real: manipulating growth-hormone signaling can produce measurable biological effects.
But producing a biological effect is not the same as demonstrating a long-term health benefit.
Growth hormone and IGF-1 signaling affect glucose metabolism, fluid balance, tissue growth and numerous other systems. Long-term manipulation of this pathway deserves considerably more scrutiny than the phrase “anti-aging peptide” implies.
FDA has identified limited safety information and potential concerns with ipamorelin and has reported serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reactions.
Verdict: Pharmacologically active does not mean proven to improve longevity or proven safe for long-term wellness use.
AOD-9604 - The “Fat-Burning” Peptide
AOD-9604 is a modified fragment related to human growth hormone and is promoted as a way to stimulate fat metabolism without the broader effects of growth hormone.
That sounds compelling.
Unfortunately, compelling mechanisms do not necessarily translate into meaningful clinical weight loss. GLP1 peptides, however, are safe and highly effective when prescribed correctly for the right patient.
Human evidence supporting substantial weight-loss benefits is limited, and FDA has cited insufficient safety information as well as concerns regarding immunogenicity and peptide characterization.
Verdict: An attractive theory with substantially less clinical evidence than modern FDA-approved obesity treatments.
MOTS-c - The “Mitochondrial” Peptide
MOTS-c may be one of the most scientifically intriguing peptides in the longevity conversation.
It is a mitochondrial-derived peptide being investigated for potential roles in metabolism, cellular stress responses, insulin sensitivity and aging. That research deserves attention.
But calling something a “longevity peptide” skips several very large scientific steps.
FDA has stated that it has not identified human exposure data for drug products containing MOTS-c and lacks sufficient information to determine whether it could cause harm when administered to humans.
Verdict: Altering cellular growth can lead to irregular cell growth, cancer. Exciting research target. Experimental therapy.
GHK-Cu - Skin & Hair
GHK-Cu is a naturally occurring copper-binding peptide that has generated interest in skin remodeling, wound healing, and hair biology.
Here, route of administration matters enormously.
Topical cosmetic use is not equivalent to systemic injection. FDA has specifically raised concerns about injectable compounded GHK-Cu, including potential immunogenicity and limited human safety data. Injecting a heavy metal into your body can have serious consequences.
Verdict: Interesting dermatologic science, particularly topically. Injectable use is an entirely different proposition.
“But My Clinic Gets It From a Compounding Pharmacy”
Maybe… This is another important distinction. And likely something that you, the patient, is not even be aware of.
A compounded medication is not the same as a random vial purchased from an overseas research-chemical website. But outsourced compounded does not mean FDA-approved, either.
FDA does not evaluate compounded medications for safety, effectiveness, or quality before they reach patients. Federal law also places restrictions on which bulk drug substances may be used in traditional 503A compounding pharmacies and 503B outsourcing facilities.
The regulatory status of many popular peptides is complicated and evolving. So the question shouldn't simply be:
“Can I buy this peptide?”
A better question is:
“What quality of human evidence supports putting this molecule into my body, and what do we actually know about its long-term safety?”
Why We're Still Very Excited About Peptide Medicine
None of this means peptide medicine should be dismissed. Quite the opposite.
The ability to design molecules that precisely influence receptors, hormones and cellular signaling pathways could transform areas of medicine ranging from obesity and metabolic disease to tissue repair, dermatology and perhaps eventually aspects of healthy aging.
But medicine has seen promising compounds fail many times between the laboratory and the pharmacy.
- Some don't work in humans.
- Some work but cause unexpected toxicity.
- Some have benefits that turn out to be smaller than expected.
And occasionally, the adverse consequences of manipulating a biological pathway don't become apparent until much later. That is why clinical trials exist.
Our Philosophy at Aesthera
We are watching peptide science very closely. We are excited by it. But excitement is not a substitute for scientific evidence in humans.
Our standard is not whether something is popular on social media, is asked for and profitable, is available from a pharmacy, or is being offered by other wellness clinics.
The questions we ask are:
- Does it work?
- Do we know what is in it?
- Do we understand the dose?
- Do we understand the short and long term risks?
- And is there enough human evidence to justify exposing our patients to those risks?
There will almost certainly be more peptide-based therapies in the near future. Some of today's experimental compounds may ultimately become important medicines just like insulin and GLP1 medications are now.
Others will disappear when human trials arrive.
Until then, there is an enormous difference between being open-minded about emerging science and being willing to use our patients as the experiment.
At Aesthera, we value your longevity above all else.
To your health,
Dr. Malzone
*Summary table for reference
| Peptide | Marketed for | Best human evidence | FDA status |
| BPC-157 | Injury, gut | Preclinical only; 1 flawed case series |
Not approved |
| TB-500 / Tβ4 | Tissue repair | Phase II dermal ulcers; no MSK data |
Not approved; banned in sport |
| CJC-1295 + ipamorelin | GH boosting | ↑GH/IGF-1 in RCTs; no clinical outcomes |
Not approved; program discontinued |
| AOD-9604 | Fat loss | Negative/modest phase II; development halted |
Not approved |
| MOTS-C | Metabolism, performance |
Preclinical only | Not approved |
| Thymosin α-1 | Immune support | Extensive (HBV, COVID, sepsis); phase III sepsis negative |
Approved abroad; US-restricted 2023 |
| GHK-Cu | Skin, wounds | Small topical cosmetic RCTs |
Not approved (cosmetic/topical use only) |
